Sotheby’s has finally revealed what its plans are for Breuer’s building. Today, the international auction house, alongside ...

Since BlackRock’s appointment as Investment Manager on 1 April 2012. 4 Further details are given in the Glossary in the Half Yearly Financial Report. Equity market investors sought alternative assets ...

Based in Cambridge, UK, AstraZeneca is a biopharmaceutical company that researches, develops, manufactures and commercializes innovative prescription medicines. The company works with primary and ...

AstraZeneca announced a strategic research collaboration with CSPC Pharmaceuticals to advance AI-enabled drug discovery. This partnership aims to develop novel o ...

Which AstraZeneca's product candidate has the potential to become a 'blockbuster'? From the Cambridge-based company's cardiovascular portfolio, the most promising experimental drug I highlight is ...

AstraZeneca succeeded in thwarting Pfizer's takeover plans – but was forced to promise investors that it could deliver very rapid growth – forecasting revenues of $45 billion by 2023, compared ...

AstraZeneca recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast cancer.

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

May 30 (Reuters) - Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its ...

Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.